Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 1 1

Status

Recruiting 6Completed 6Unknown 2Not yet recruiting 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 6OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 4Lymphoid 2Other hematologic neoplasm 1

Conditions

Breast Neoplasms 1401Neoplasms 1128Prostatic Neoplasms 745Lung Neoplasms 621Colorectal Neoplasms 599Carcinoma, Non-Small-Cell Lung 570Carcinoma, Hepatocellular 414Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 356Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 310Head and Neck Neoplasms 290Neoplasm Metastasis 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 254Uterine Cervical Neoplasms 248Recurrence 248Melanoma 243Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 214Sarcoma 209Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 182

Interventions

siltuximab 2tocilizumab 1talquetamab 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × OTHER × Cytokine Release Syndrome × Clear all
NCT06377059 2026-05-15

Early Detection of Complications During Immunotherapy for Haematological Malignancy

Rigshospitalet, Denmark

Phase NA Recruiting
100 enrolled
Other hematologic neoplasm

Cytokine Release Syndrome, Hematologic Neoplasms

NCT06421675 2026-04-27

EMBRACE

Ontario Clinical Oncology Group (OCOG)

Phase 2 Recruiting
40 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT05972135 2026-04-22

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Recruiting
100 enrolled
Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

University of Utah

Phase NA Recruiting
40 enrolled
LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
20 enrolled
Plasma cell

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06447376 2025-05-11

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Case Comprehensive Cancer Center

Phase 1 Recruiting
20 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡